Okimus (Quinine)

Quick links

Choose a section

Quick links to important sections

Advertisements

Okimus (Quinine)

Advertisements
Advertisements

Treatment option: Malaria, Night Leg Cramps, Leg Cramps

Advertisements

Overview of Okimus (Quinine)

Quick Facts

Property Description
Active ingredient Quinine (sulfate or dihydrochloride)
Form Oral capsules/tablets, Parenteral solutions
Pharmacological class Antimalarial, Antiprotozoal
Common use Control of parasitic blood infections
Origin Naturally derived alkaloid (Cinchona bark) or synthetic

What is Okimus: Definition, Class, and Purpose

Okimus is a medication defined by its active ingredient, quinine, which belongs to the quinoline class of antimalarial and antiprotozoal agents. Its primary general purpose is to fight and control parasitic infections in the bloodstream, particularly those caused by the severe strain, Plasmodium falciparum. Quinine is recognized as a treatment of international importance in public health and is included on standard lists of essential medicines for this purpose.

Quinine is a foundational compound in pharmacology, chemically classified as an alkaloid. As a single-ingredient product, its general use is centered on its ability to rapidly clear these parasites from the blood, contributing to the resolution of the acute systemic symptoms associated with the infection. Its effectiveness against drug-resistant strains in particular has been established through extensive clinical use.


Quinine: Composition, Forms, and Origin

The active component of Okimus is quinine, usually presented as a salt such as quinine sulfate (commonly in oral forms) or quinine dihydrochloride (used for injection), which dictates the final dosage form and administration route. Quinine is an alkaloid compound originally extracted from the bark of the Cinchona tree, although the substance is also widely produced through synthetic means today.

The medication is manufactured for both oral and intravenous routes of administration; common dosage forms include capsules or tablets for swallowing and sterile parenteral solutions for injection. Quinine is an antiprotozoal agent used to treat malaria by interfering with parasitic processes; its core identity is tied to its capability to disrupt these harmful microorganisms.


How is Okimus Used Generally?

Okimus is used generally to provide effective blood schizonticide activity, meaning it kills the parasitic organisms during their multiplication phase within the red blood cells. By stopping the parasite from multiplying in the bloodstream, the medication helps to control the acute infection and mitigate its overall impact on the patient—for example, when a patient presents with uncomplicated P. falciparum infection.

Beyond its primary function as an antimalarial, quinine possesses auxiliary benefits through its mild antipyretic (fever-reducing) and analgesic (pain-relieving) properties. These non-specific physiological effects contribute to patient comfort by helping to alleviate common systemic symptoms like fever and general aches associated with the infection.

Regulatory References

  1. WHO Essential Medicines Lists
  2. MedlinePlus Drug Information
Advertisements

What side effects are possible with Okimus (Quinine)?

Possible Side Effects and Safety Information

The safety profile of quinine, the active ingredient in Okimus, is formally documented in government regulatory records and is defined by both common and rare, serious adverse reactions.

Adverse Reaction Categories

Many of the drug's most frequent adverse effects are grouped into a set of symptoms known as Cinchonism, which are often dose-related and typically reversible. These effects predominantly involve the ear and labyrinth disorders (e.g., tinnitus and hearing impairment), nervous system disorders (e.g., headache, dizziness), and gastrointestinal disorders (e.g., nausea and vomiting), which are often classified as Very Common or Common in official labeling.

Serious Adverse Reactions

Official regulatory documents emphasize the potential for serious adverse reactions that are classified as Rare or Uncommon. These include life-threatening complications such as severe hypoglycemia, which can occur rapidly after administration, and serious cardiac arrhythmias, including QT interval prolongation and Torsade de Pointes. Furthermore, severe and potentially fatal hematological disorders, such as acute hemolytic anemia and Thrombotic Microangiopathy, have been documented.

Population-Specific Safety Constraints

Specific safety constraints are mandated in official labeling. For instance, the risk of red blood cell breakdown (hemolysis) is increased in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency). Caution is also specified for individuals with pre-existing cardiac conditions or Myasthenia Gravis. Regulatory limitations also include contraindications for individuals with known hypersensitivity to quinine, pre-existing tinnitus, or optic neuritis.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose with quinine is officially documented as presenting with the severe symptom cluster known as Cinchonism. Manifestations include significant tinnitus, hearing impairment, headache, and profound ocular effects such as blurred vision, defective color perception, and potential for visual field constriction. Severe toxicity carries the risk of permanent blindness or deafness.


Serious Outcomes and Immediate Actions

The most serious outcomes documented in regulatory labeling are related to the cardiovascular and metabolic systems. These include QT prolongation with the risk of life-threatening ventricular arrhythmias, such as torsades de pointes, along with seizures and severe hypoglycemia (low blood sugar), which can escalate to coma and death.

Immediate medical attention must be sought for any suspected overdose. Regulators state that individuals must contact a Poison Control center or call 911 (or equivalent emergency services) for serious symptoms, including passing out or trouble breathing. Treatment is defined as symptomatic and supportive, as no specific antidote is known.


Monitoring and Special Considerations

Hospital monitoring is required for overdose management, focusing on continuous assessment of cardiac rhythm (ECG) and blood glucose levels. Regulatory notes indicate that the risk of toxicity is increased in patients with severe renal impairment, and there is a documented increased risk of severe hypoglycemia during overdose in pregnancy.

Advertisements

Therapeutic Uses of Okimus (Quinine)

What Okimus (Quinine) Treats: Main Uses and Benefits

Okimus (Quinine) is applied to provide symptomatic relief in specific clinical scenarios, which may assist with easing the overall symptom burden. It is applied in contexts where symptoms become noticeable or create temporary functional strain. The medication is relevant across two main therapeutic contexts against symptoms related to physical discomfort.


Managing Heightened Symptoms

This medication is commonly used to help with the symptomatic management of uncomplicated malaria and is also applied in addressing recurrent, disruptive nocturnal leg cramps. It may assist with addressing symptom clusters that may become intense or disruptive, such as high fevers, chills, generalized discomfort, and acute muscle spasms. This provides support that may assist with managing difficult episodes and contributes to easing the overall symptom load during periods of heightened distress.

Quick Fact: Addresses Symptoms Related to Muscle Cramps


Addressing Symptom Intensity

Quinine is relevant in contexts involving heightened systemic burden. It is used in situations involving certain distressing symptoms, contributing to improved comfort during periods of heightened symptoms by easing the overall symptom load. This provides supportive relief when symptoms intensify, which may assist the patient during challenging symptomatic phases.

Regulatory References

  1. UK Patient Information Leaflet for Quinine Sulfate
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Okimus (Quinine)

This information is based strictly on authoritative governmental regulatory documents regarding patient eligibility and non-eligibility.

Populations Who Must Not Use Quinine (Contraindications)

Classification Exclusion Criteria (Must Not Use)
Cardiovascular/Ocular Patients with a Prolongation of the QT interval or Optic neuritis.
Neuromuscular Individuals with Myasthenia gravis.
Hypersensitivity/Hematologic Those with known hypersensitivity to quinine, quinidine, or mefloquine, or a history of quinine-associated thrombocytopenia, TTP/HUS, or Blackwater fever.

Eligibility Restrictions and Special Populations

Quinine use is allowed primarily for adults. Specific restrictions apply to other groups:

  • Organ Impairment: The medicine is contraindicated in severe hepatic impairment (Child-Pugh C). Patients with severe chronic renal impairment require mandatory dose adjustment.
  • Age Groups: Although used in children for the approved indication, official pediatric use is not established for non-malaria indications (e.g., nocturnal leg cramps). Older adults require close monitoring due to altered drug clearance.
  • Pregnancy and Lactation: Use during pregnancy is generally restricted to situations where the benefit justifies the risk (Pregnancy Category C). Use in nursing mothers requires caution and is discouraged if the infant has G6PD deficiency.
Advertisements

What should I know about interactions with other medicines?

Official Regulatory Information for Okimus (Quinine) Interactions

Official regulatory documentation structures the Quinine interaction profile around metabolic interference, additive pharmacodynamic effects, and severe cardiac risk.

Contraindicated Combinations

The most significant restriction is the formal prohibition of co-administration with other medicinal products known to prolong the QT interval (e.g., Class IA and Class III antiarrhythmics). Use is also contraindicated with CYP3A4-sensitive drugs that may prolong the QT interval (e.g., Astemizole, Cisapride, Terfenadine) and other antimalarials such as Halofantrine and Mefloquine. Co-administration with Neuromuscular blocking agents is avoided due to the potential for potentiation of effects.

Metabolic and Exposure Interactions

Quinine is officially documented as an inhibitor of CYP3A4 and CYP2D6, requiring monitoring when co-administered with substrates of these enzymes (e.g., Atorvastatin). The drug's own clearance is sensitive to inhibitors (e.g., Erythromycin) and inducers (e.g., Rifampin), with the latter associated with reported treatment failures. Clearance of co-administered substances like Digoxin (reduced biliary clearance) and Amantadine (reduced renal clearance) is also officially documented to be altered.

Other Documented Interactions

  • Pharmacodynamic Effects: Quinine may enhance the effects of anticoagulants (risk of hypoprothrombinaemia) and oral hypoglycaemics (increased risk of hypoglycemia) as stated in regulatory labels.
  • Timing Requirement: Antacids containing magnesium or aluminum should not be taken concurrently; a time separation is required to avoid interference with Quinine's absorption.
  • Population Note: Clearance of Quinine is officially decreased in patients with severe chronic renal impairment, and administration is generally restricted in severe hepatic impairment (Child-Pugh C) due to altered exposure.
Advertisements

Mechanism of Action

Heme Detoxification Interference

Okimus (Quinine) primarily acts within the parasite's digestive vacuole, a domain involving heme polymerization. It binds to the toxic free heme released from digested host hemoglobin, preventing its conversion into the inert crystalline structure, hemozoin. This interference initiates a toxic cascade, resulting in the accumulation of cytotoxic heme and subsequent disruption of key cellular functions within the parasite.


Nucleic Acid and Protein Synthesis Modulation

The drug engages mechanisms that regulate molecular synthesis within the parasite. Quinine modulates key pathways by inhibiting DNA replication and protein synthesis. This effect on genetic material and essential building blocks results in the suppression of parasite cell division and overall growth rate, leading to an alteration in the parasite's internal regulatory homeostasis.


Membrane and Ion Channel Interaction

Quinine also exhibits effects on cell membrane function and ion channel activity, a distinct mechanistic domain. It engages mechanisms that regulate voltage-gated sodium channels in excitable host tissues, causing reduced excitability and resulting in a decrease in action potential firing frequency within muscle fibers.

Advertisements

Dosage and Administration Information

How to Use Okimus (Quinine)

Quinine is used according to strict protocols that define its administration route, dosing, and duration based on the condition being addressed. The medicine is utilized in two principal forms, contingent upon the patient's state and ability to take oral medication.


Official Administration Guidelines

Instruction Official Guideline
Route of Administration Oral (capsules/tablets) is used for uncomplicated illness. Intravenous (IV) Infusion is reserved for severe conditions or when oral administration is not possible.
Standard Dosing Schedule The standard oral dose for adults is 648 mg taken every 8 hours (q8h). For severe cases, an IV loading dose of 20 mg/kg is administered by slow infusion, followed by maintenance doses of 10 mg/kg every 8 to 12 hours.
Timing in Relation to Meals Oral capsules must be taken with food to help mitigate gastrointestinal effects.
Total Course Duration The complete course of treatment typically lasts 7 days, including the time spent on IV and subsequent oral therapy.

Procedural Instructions and Adjustments

Intravenous quinine must always be administered by slow infusion over approximately 4 hours and should never be given as a rapid injection. The concentrated solution requires dilution prior to administration.

Dose Adjustments: For patients with severe chronic renal impairment, the oral dosing schedule is modified to 324 mg every 12 hours after an initial 648 mg dose. Furthermore, the IV loading dose must be omitted if the patient has received quinine or similar medications within the previous 12–24 hours. Therapy must transition from IV to oral administration as soon as the patient is able to swallow to complete the full 7-day course.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Okimus (Quinine)

Evidence for Use in P. falciparum Malaria Control

Quinine was studied for the control of parasitic blood infections, specifically those caused by the Plasmodium falciparum parasite. The body of evidence includes a large number of Randomized Controlled Trials (RCTs), where different approaches were studied, alongside extensive Systematic Reviews and Meta-Analyses that pool data from many trials. This research has examined outcomes related to systemic or functional imbalance in patients with both uncomplicated and severe infections.

Studies monitored several key measures, including measures of the infection's course. These included the Parasite Clearance Time (PCT), which is the time it takes for the parasite to be undetectable in the blood, and the Fever Clearance Time (FCT), or how quickly the fever subsides. Trials reported patterns related to the resolution of parasitemia (parasite presence) in the bloodstream. However, the outcomes, such as rates of treatment failure (where the infection returns), findings were mixed depending on the geographic area and whether the parasites in that region were resistant to other drugs.

Evidence for the Symptomatic Management of Nocturnal Leg Cramps

Research explored quinine in the context of outcomes related to physical discomfort and episodic or acute changes associated with frequent, disruptive nocturnal leg cramps. The primary research consists of short-term, placebo-controlled crossover trials. These designs allow researchers to observe differences between quinine and an inactive dummy pill (placebo) in the same patient, often over a period of approximately four weeks.

These trials primarily examined the change in the frequency of nocturnal leg cramps—specifically, how often they occurred. Studies reported patterns indicating a difference in the frequency of nocturnal leg cramps compared to placebo treatments. However, research exploring outcomes related to symptom intensity or variability suggests that observed measurements did not differ significantly regarding the severity or the duration of an individual cramp episode. Evidence is limited to the short-term time frames defined in the original trials.

Key Studies & References

  1. Label: QUININE SULFATE- quinine capsule - DailyMed / FDA Label
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Okimus (Quinine) (FAQ)

Q: Does this medicine make you sleepy (drowsy)?

A: Official regulatory documents and safety data for the single-ingredient product indicate that drowsiness is not listed among the common or frequent side effects. Known side effects, including less common ones, are thoroughly documented in the full safety information section of the product labeling.

Q: Is this product safe to use for children 2 years old?

A: Regulatory information indicates that this over-the-counter product is not intended for use in children younger than 2 years of age unless specific guidance is provided by a doctor. Information regarding use in young children can be found on the official product label and should be discussed with a healthcare professional.

Q: Where should I store this medicine?

A: Official labeling advises storing the medicine at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). It is important to avoid keeping the product in areas subject to excessive heat, such as above 40 C (104 F). The label provides full storage details.

Q: Can I take this if I have high blood pressure?

A: Regulatory product information may caution that individuals with certain pre-existing conditions, such as high blood pressure or heart problems, are advised to discuss the use of this medicine with a doctor. The official warnings and precautions section advises extra care for these patient groups.

Advertisements

How should Okimus (Quinine) be stored and disposed of?

Storage and Disposal Requirements for Quinine

Quinine must be stored under specific environmental conditions to maintain its stability and product integrity. The medication must be kept out of the reach of children.


Mandatory Storage Conditions

Requirement Official Regulatory Instruction
Temperature Store at or below 25°C (77°F). Keep from freezing.
Protection Protect from light and moisture.
Container Keep container tightly closed in a tight container.

Disposal Instructions

Unused or expired quinine must be disposed of in accordance with all applicable local, regional, and national regulations. Regulatory guidance recommends utilizing drug take-back programs as the preferred method. The product should not be released into the environment and must be prevented from reaching drains or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Okimus (Quinine) found in:

A-Z Index: